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bilberry extract (Mirtoselect®) group and 10 sub-
jects in the placebo group completed the clini-
cal study. Schirmer’s test values indicating the 
volume of tear secretion were significantly im-
proved in the bilberry extract group (p=0.019), 
whereas no significant changes were observed 
in the placebo group. A subset analysis revealed 
that Mirtoselect® could be more effective in sub-
jects with higher tendency of dry eye. In terms 
of antioxidant potential, the bilberry extract pro-
duced significant improvement of BAP (p=0.003) 
and an increase of modified BAP/d-ROMs ratio, 
an indicator of overall balance between antioxi-
dant potential and oxidative stress.
CONCLUSIONS: Our results suggested that 
natural, standardized bilberry extract (Mirtose-
lect®) is a natural more bioavailable delivery 
form anthocyanins, suggesting a strong matrix 
effect exerted by the non-anthocyanin compo-
nent. Furthermore, it can improve tear secretion 
and plasmatic antioxidant potential in subjects 
suffering from DED symptoms.
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Introduction
According to the definition proposed by the In-
ternational Dry Eye Workshop (DEWS) in 2007, 
dry eye is “a multifactorial disease of the tears 
and ocular surface that results in symptoms of di-
scomfort, visual disturbance, and tear film insta-
bility with potential damage of the ocular surface. 
It is accompanied by increased osmolarity of the 
tear film and inflammation of the ocular surface”1. 
Abstract. – OBJECTIVE: Dry eye, a chronic 
disease of lachrymal fluid and corneo-conjuncti-
val epithelium, could significantly impact visual 
function, affects quality of life and work produc-
tivity. Beside several conventional treatments, 
nutritional supplements based on bilberry ex-
tract have been identified as effective contrib-
utors to eye health. Here, we aim at investigat-
ing the bioavailability of a standardized bilberry 
extract, its ability to alleviate dry eye symptoms 
and its antioxidant potential. 
MATERIALS AND METHODS: Either bilberry 
dried standardized extract derived from Vaccini-
um myrtillus L. fresh frozen fruits (Mirtoselect®) 
or a highly purified anthocyanin-rich extract, de-
void of the non anthocyanin component and sup-
ported on maltodextrins, were each orally ad-
ministrated to 5 male rats. Blood samples were 
collected at 5, 10, 15, 20, 30, 45, 60, 90, 120 min-
utes after treatment, processed and analyzed 
by UV spectrophotometric method. In a parallel 
analysis, 22 otherwise healthy subjects suffer-
ing from dry eye symptoms were enrolled ran-
domly assigned to receive the more bioavailable 
bilberry extract or placebo. Ophthalmological 
and clinical examinations including Schirmer’s 
test, pupil constriction, diacron-reactive oxygen 
metabolites (d-ROMs) test and biological antiox-
idant potential (BAP) test were performed at in-
clusion and after the 4-week study period. 
RESULTS: The area under the curve of plas-
matic levels of anthocyanosides in rats result-
ed 202.34±24.23 µg·min/ml for Mirtoselect® and 
130.93±4.93 µg·min/ml for the highly purified an-
thocyanin-rich bilberry extract, notwithstanding 
the fact that the highly purified anthocyanin-rich 
extract group received an anthocyanins dosage 
much higher than the Mirtoselect® group (354 
mg/Kg in anthocyanosides vs. 136 mg/Kg in an-
thocyanosides). 21 subjects, 11 subjects in the 
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Dry eye disease (DED) represents a common cli-
nical problem, with a prevalence ranging from 
5% to 35% at various ages, and around 5 million 
of Americans aged more than 50 years suffering 
from this condition1. European and Asian popu-
lations have a similar prevalence; a large popu-
lation-based study in Japan revealed that pre-
valence of mild to severe, clinically diagnosed 
DED in men and women were 12.5% and 21.6%, 
respectively2. There are several recognized risk 
factors for the development of DED, including 
aging, female gender, hormonal changes, dietary 
imbalances (omega-3 essential fatty acids or vita-
min A deficiencies), metabolic or immunological 
disorders and viral infections3-7. Also, one of the 
major factors involved in the onset of dry eye is 
thought to be the use of visual display terminal 
(VDT) at work8. However, recent technical inno-
vations have made display terminals smaller and 
less expensive: notebook PCs, tablet terminals, 
handy terminals such as smartphones and portable 
video game consoles are rapidly spreading. As a 
result, eyes are increasingly strained also at home; 
therefore, the number of DED patients is expected 
to further increase. Dry eye could significantly 
impact visual function, which in turn affects qua-
lity of life and work productivity. The primary go-
als of DED treatment are relief of symptoms, im-
provement of visual acuity and patients’ comfort 
and restoration of normal ocular surface and tear 
film; pharmacological and non-pharmacological 
strategies for DED range from dietary and life-
style modifications, artificial or autologous tear 
substitutes, punctal plugs, and topical and/or sy-
stemic anti-inflammatory medications to surgery9. 
However, correct management should take into 
account patient’s preference and must maintain 
a balance between efficacy and safety. Beside 
conventional treatments, nutritional supplements 
have been reported to be effective contributors to 
eye health10. Among supplement foods, bilberry, 
a type of shrub in Ericaceae family, which grows 
in Northern and Central Europe, is currently in-
vestigated for its antioxidant properties, capillary 
vessels protection and treatment of ocular disor-
ders11. In particular, dietary supplementation with 
bilberry extract alone or combined with other in-
gredients safely improved subjective symptoms 
of computer eye strain12 or asthenopia13. So far, 
no direct evaluation has been made on the effect 
of bilberry in alleviating DED symptoms. Despi-
te the most important pharmacologically active 
component in bilberry extract is anthocyanoside 
flavonoids (anthocyanins), several other active 
constituents such as vitamins, sugars, pectins and 
tannins can influence their biological effects14. In 
this study, we compared two different oral formu-
lations for their bioavailability in rats: natural bil-
berry extract with standardized anthocyanins and 
full range of non-anthocyanin components (Mir-
toselect®), and highly purified anthocyanin-rich 
extract supported on maltodextrins. The prepara-
tion which resulted more bioavailable was then 
investigated in a randomized study in humans for 
its ability to alleviate dry eye symptoms and im-
prove antioxidant potential in subjects with DED 
symptoms.
Materials and Methods
In vivo Pharmacokinetic Study
Male Sprague-Dawley rats (190-220 g) were 
maintained at 23±1°C under a controlled 12-hour 
light/dark cycle with free access to tap water and 
standard food for 3 days before the experiment. 
After 16-hour starvation, the rats were randomly 
assigned into two groups of 5 animals each. An-
thocyanosides extracts, namely bilberry dried ex-
tract derived from Vaccinium myrtillus L. fresh 
frozen fruits (Mirtoselect®, Indena, Milan, Italy), 
containing 36% anthocyanins and matching the full 
phytochemical profile of the whole fruit, and a hi-
ghly purified anthocyanin-rich extract, containing 
89% anthocyanins and devoid of the non anthocya-
nin fraction, were orally administrated at 400 mg/
kg body weight dissolved in water. Under ether 
anesthesia, blood samples were collected at 5, 10, 
15, 20, 30, 45, 60, 90, 120 minutes after treatment. 
The blood samples (0.5 ml) were centrifuged with 
10% trichloroacetic acid (0.5 ml) at 5800 rpm for 5 
minutes. Supernatants were collected. Pellets were 
resuspended in 5% trichloroacetic acid (1 ml) and 
centrifuged at 5800 rpm for 5 minutes. Superna-
tants were collected, gathered and analyzed by UV 
spectrophotometric method at 530 nm.
Subjects and Clinical Study Design
This was a randomized, double-blinded, place-
bo-controlled, parallel group comparison study. 
Otherwise healthy subjects who had fulfilled the 
inclusion criteria without presenting any of the 
exclusion criteria and agreed on voluntary parti-
cipation at a pre-study explanation meeting were 
selected.  
Inclusion criteria were:
- healthy subjects aged from 30 to 60 years, suf-
fering from visual fatigue or eye strain;
A. Riva, S. Togni, F. Franceschi, S. Kawada, Y. Inaba, R. Eggenhoffner, L. Giacomelli
2520
- subjects who daily use video game consoles or a 
PC, or operate VDT for at least 4 hours per day;
- subjects who have total corrected visual acuity 
of at least 1.0 for both eyes, if a refractive error 
exists, it should be properly corrected;
- subjects who do not regularly use pharmaceuticals 
or health foods that are effective for eye strain.
Exclusion criteria were:
- subjects who have a treatment history of car-
diac failure or cardiac infarction;
- subjects who are being treated or taking medi-
cations due to chronic diseases;
- subjects who are allergic to food related to the 
investigational product or pharmaceuticals;
- subjects who are using contact lenses;
- subjects who have eye diseases, entropium pal-
pebrae, or entropium ciliarum;
- subjects who smoke;
- subjects who have poor eating habits;
- subjects who do not have a sufficient sleep;
- women during pregnancy and breast-feeding, 
or women of childbearing potential.
The study was conducted in compliance with the 
Declaration of Helsinki (adopted in 1964, revised 
in 2008) and received Ethic approval by the Sei-
shin-kai Medical Association, Inc., Takara Clinic 
(Chairman, Tsuyoshi Takara). The study coordina-
tion and interpretation were conducted in Italy. All 
subjects signed a written informed consent before 
entering into the study. Participants were randomly 
assigned to either dietary supplement or placebo. 
The supplement finished dosage form was formu-
lated in tablets, each consisting of 80 mg of Mirto-
select® (the bilberry standardized extract resulting 
more bioavailable in the animal study) and 170 mg 
of standard excipients, whereas placebo comprised 
excipients only. Participants received 2 tablets of 
Mirtoselect® (corresponding to 160 mg Mirtose-
lect®) daily or placebo for 4 weeks. 
To reproduce the conditions of visual load by 
VDT use, participants were instructed to play on 
a video game console for 45 minutes before exa-
mination.
Ophthalmological and clinical examinations 
were performed at inclusion and after the 4-week 
study period at Ario Nishi-arai Eye Clinic (Tokio, 
Japan), and included:
- Schirmer’s test15 to evaluate the volume of 
tear secretion was carried out by using Col-
orBar stripsTM (Eagle Vision, Inc., Memphis, 
TN, USA). In details, the strips were placed on 
the lower eyelids and left for 5 minutes under 
spontaneous blinking; the length of the moist-
ened part measured by a calibrated scale on the 
strip indicated the tear flow. A subset analysis 
was also performed by classifying participants 
as subjects with severe eye dry symptoms 
(Schirmer’s test ≤ 10 mm) and subjects with 
mild symptoms (Schirmer’s test > 10 mm).
- Pupil constriction was measured before and 
after the visual load by using TriIRIS® C9000 
(Hamamatsu Photonics K.K., Hamamatsu City, 
Japan) and the amount of change was used as 
an indicator of eye strain.
- Oxidative stress and antioxidant potential were 
evaluated by diacron-reactive oxygen metabo-
lites (d-ROMs) test and biological antioxidant 
potential (BAP) test respectively, through free 
radical analytical system (FRAS) (Wismerll, 
Co., Ltd., Tokyo, Japan). d-ROMS test mea-
sures the concentration of blood hydroperoxide 
(ROOH). BAP test measures the inhibition of 
oxidation through electron transfer to active 
oxygen in plasma. In addition, modified BAP/
d-ROMs ratio (as BAP/d-ROM/7.541)16 was 
calculated for comprehensive evaluation of the 
antioxidant potential of the body. 
Statistical Analysis
Intragroup and intergroup comparisons were 
performed by using paired t-test and unpaired 
t-test, respectively. Multiple comparisons were 
performed by using ANOVA test with post-hoc 
Bonferroni correction. Statistical analysis was 
performed by IBM SPSS 18.0 software (SPSS 
Inc. Chicago, IL, USA). p-value <0.05 was consi-
dered significant.
Results
In vivo Pharmacokinetic Study
As shown in Figure 1, the plasma anthocya-
nosides level in male rat that received 400 mg/
kg Mirtoselect® bilberry extract (136 mg/Kg in 
anthocyanosides) was much higher than that of 
rats that received 400 mg/kg of the highly puri-
fied anthocyanins-rich fraction (354 mg/Kg in an-
thocyanosides); the areas under the curve (AUC) 
were 202.34±24.23 vs. 130.93±4.93 µg·min/ml, 
respectively. The relative bioavailability of Mirto-
select® compared to the highly purified anthocya-
nins-rich fraction, expressed as the ratio of the 
dosage adjusted-AUC values, resulted 4.
Clinical Study
Overall 22 subjects (8 men and 14 women) at the 
mean age of 45.5 ± 7.3 years were enrolled in the 
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study. As one participant dropped out during the 
study period for personal reasons, the final analy-
sis set included 21 participants: 11 subjects (3 men 
and 8 women, 43.5 ± 5.1 years old) in the bilberry 
extract group and 10 subjects (5 men and 5 women, 
48.8 ± 8.3 years old) in the placebo group. 
Schirmer’s Test
The results of Schirmer’s test before and after 
4-week study period for right and left eye and the 
means of both eyes are shown in Table I. Signifi-
cant improvements in the mean values for right 
eye (p = 0.009) and both eyes (p = 0.019) as well 
as a beneficial tendency for left eye (p = 0.062) 
were observed in the group treated with bilberry 
extract. In the placebo group, the mean values of 
Schirmer’s test increased compared to the baseline 
for right eye (p = 0.361), left eye (p = 0.118) and 
both eyes (p = 0.177) but the differences were not 
significant. In addition, mean improvement rates 
from baseline to 4-week were higher in the bilber-
ry extract group than in the placebo group for ri-
ght eye, left eye and both eyes, with a statistically 
significant difference for the right eye (p = 0.049). 
Given that the results of Schirmer’s test at inclu-
sion ranged from 5 to 35 mm for both eyes with a 
wide individual variation, we performed a subset 
analysis to examine whether the symptom seve-
rity influenced the effects of the investigational 
products. Participants were classified in subjects 
with severe symptoms of dry eye (dry condition) 
and subjects with mild symptoms (wet condition). 
Regarding right eye, the improvement rate among 
subjects with severe symptoms was higher in the 
bilberry extract group than in placebo group (p = 
0.015). Among subjects with mild symptoms, no 
significant difference was observed between the 
bilberry extract group and the placebo group (p 
= 0.131). In the bilberry group, the improvement 
rate in participants with dry condition was signi-
ficantly higher than that of participants with wet 
condition (p = 0.028). In the placebo group, no si-
gnificant difference was recorded between the dry 
condition and the wet condition (p = 0.516). Simi-
lar results were obtained for the left eye; improve-
ment rate for subjects with severe symptoms ten-
ded to be higher in the bilberry extract group than 
in the placebo group (p = 0.067). Among partici-
pants with mild symptoms, there was no signifi-
cant difference between the bilberry extract group 
and the placebo group (p = 0.986). In the bilberry 
group, improvement rate of the participants with 
severe condition was significantly higher than that 
of participants with the wet condition (p = 0.023). 
No significant difference between the dry condi-
tion and the wet condition was observed in the 
placebo group (p = 0.770).
Pupil Constriction
No significant differences were observed in ter-
ms of pupil constriction measurements between 
before and after visual load (data not shown).
Oxidative Stress and Antioxidant 
Potential
Figures 2-4 show the results of d-ROMs test, 
BAP test and the modified BAP/d-ROMs ratio, 
respectively. In the bilberry extract group, only 
BAP significantly increased (p = 0.003) during the 
study period; d-ROMs (p = 0.152) and modified 
BAP/d-ROMs (p = 0.187) ratio did not signifi-
cantly change. In the placebo group, d-ROMs in-
creased significantly (p = 0.013); BAP increased 
(p = 0.141) while modified BAP/d-ROMs ratio 
decreased (p = 0.293), but these changes were not 
statistically significant. 
Discussion
The aim of this study was to investigate the abi-
lity of bilberry extract to alleviate dry eye symp-
toms and its antioxidant potential. To identify oral 
bilberry extract formulations with high bioavaila-
bility, we firstly compared two preparations: na-
tural bilberry extract with standardized anthocya-
Table I. Evaluation of tear secretion by Schirmer’s test.
  Bilberry extract (Mirtoselect®)            Placebo
  inclusion 4 weeks inclusion 4 weeks
Right eye (mm) 11.4±5.1 19.5±7.3** 15.3±9.5 16.9±9.8
Left eye (mm) 14.0±9.5 20.0±11.5 13.6±9.3 16.9±9.5
Both eyes (mm) 12.7±6.3 19.7±8.6* 14.5±9.3 16.9±9.3
Data are expressed as mean ± standard deviation. *p <0.05 vs. inclusion; **p <0.01 vs. inclusion.
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nins (Mirtoselect®) obtained by extracting the full 
range of the non-anthocyanin components, and 
a highly purified anthocyanin-rich fraction. In 
a previous study, these two extracts were alrea-
dy evaluated for their biological effects in a va-
riety of retinopathy conditions, and Mirtoselect® 
supplementation resulted superior than a generic 
bilberry extract (obtained by the dilution of an 
anthocyanins-rich fraction with maltodextrins) 
in ameliorating retinal circulatory parameters14. 
The authors speculated that the non-anthocya-
nin fraction of Mirtoselect®, mainly composed 
of naturally present sugars and organic acids po-
orly represented in the generic bilberry extract 
(as evidenced by 1H-NMR-HPLC analysis), can 
explain this different biological effect. It is well 
described in the literature that the natural matrix 
of a standardized extract, apparently considered 
a non-active fraction, has on the contrary an im-
portant role in the onset and the modulation of 
the biological effects of an extract17. To ensure 
their maximum effectiveness, commercial bil-
Figure 1. Plasma levels of anthocyanosides after oral administration of two different bilberry extract formulations.
Figure 2. Assessment of the plasma diacron-reactive oxygen metabolites (d-ROMs); *p<0.05.
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berry extracts should be carefully characterized 
for purity, analytical composition in active and 
non-active ingredients, and pharmacokinetic pro-
perties18. The results here described showed that 
anthocyanosides are four times more available 
when orally administrated in rat as natural bil-
berry extract (Mirtoselect®) than as an enriched 
fraction. This is of particular relevance in the 
clinical setting, as several reconstructed bilberry 
based ingredients, titrated to 36% anthocyanins, 
are in reality obtained through the dilution of hi-
ghly purified anthocyanosides with maltodextrins, 
thus completing losing the non-anthocyanins na-
tural component. The increased pharmacokinetic 
properties of standardized bilberry extracts could 
be, on the contrary, ascribed to their whole com-
ponents, as the non-anthocyanin fraction could 
contribute to enhancing the plasma content of 
anthocyanins besides exerting itself a biological 
effect. Similarly, in a recent study on Coptidis 
Rhizoma extract, the Authors indicated that pro-
teinaceous nanoparticles contained in the whole 
extract were crucial for the biological activities of 
berberine (the major active compound), because 
they acted as natural drug carriers that increased 
berberine absorption17. Previous in vivo studies 
Figure 3. Assessment of the plasma biological antioxidant potential (BAP); **p<0.01.
Figure 4. Assessment of the modified biological antioxidant potential (BAP)/diacron-reactive oxygen metabolites (d-ROMs) 
ratio in plasma.
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documented that the plasma peak concentration 
of anthocyanins was 1.2 µM at 15 minutes after 
oral administration of 400 mg/kg bilberry extract 
(153.2 mg/kg as anthocyanins)19. In addition, the 
bioavailability of anthocyanins in those rats was 
0.93%19. 30.8% and 13.4% of anthocyanins were 
recovered in urine and bile, respectively, during 
the first 4 hours following the intravenous admi-
nistration of bilberry extract19. The bilberry ex-
tract, which showed the highest bioavailability in 
in vivo pharmacokinetic studies, was then tested 
for its therapeutic relevance in DED. The standar-
dized bilberry extracts (Mirtoselect®) produced 
beneficial effects on the volume of tear secretion, 
an important parameter to evaluate DED symp-
toms measured by Schirmer’s test. As the right 
eye and mean value of both eyes in the bilberry 
extract group showed significant increase, it could 
be concluded that Mirtoselect® administration si-
gnificantly improved the tear flow parameter, dif-
ferently from placebo. In the subset analysis, par-
ticipants with higher tendency of dry eye showed 
greater improvement rate in Schirmer’s test in the 
bilberry extract group than placebo group. Consi-
stently, in the bilberry extract group, participants 
with severe symptoms of dry eye showed greater 
improvement rate than those with mild symptoms. 
Therefore, although further and larger investiga-
tions are needed, Mirtoselect® supplementation 
could be more effective in subjects with a higher 
tendency of dry eye. Bilberry extract also seemed 
to exert positive effects as antioxidant agent. In 
the bilberry extract group, no significant change 
was observed in d-ROMs, an indicator of oxida-
tive stress, while BAP, an indicator of antioxidant 
potential, significantly increased during the study 
period. Modified BAP/d-ROMs ratio, an indicator 
of overall balance between antioxidant potential 
and oxidative stress, increased in the bilberry ex-
tract group (contrary to the placebo group), indi-
cating that Mirtoselect® could exert a protective 
action against reactive oxygen metabolites. The 
results of our study support the outcomes of pre-
vious in vitro20, in vivo21 and clinical studies22 on a 
potential relationship between dry eye and reacti-
ve oxygen species23.
Conclusions
The findings of our study indicated that natural, 
standardized bilberry extract (Mirtoselect®) may 
improve tear secretion and enhance antioxidant 
potential. In particular, here we confirmed the as-
sociation between increased antioxidant potential 
and anthocyanins, the main active components of 
bilberry extract. We also showed some pharma-
cokinetic properties, and consequently therapeu-
tic effects, of bilberry extracts may be the result of 
the synergistic combination of anthocyanins with 
the other constituents, naturally present in the bil-
berry fruit. However, we are aware that our study 
lacks a complete pharmacokinetic profile of bil-
berry extracts, as well as the mechanism of action 
of bilberry extract on dry eye deserves to be de-
eply investigated in further, larger studies. As the 
volume of tear secretion measured in our study 
is only one aspect of dry eye, other indicators of 
symptoms such as tear film breakup time should 
also be examined.
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